Key Highlights
- Bone Biologics (NASDAQ:BBLG) was trading down 10.0% at USD 0.3601 in pre-market on Friday, November 13, 2026; no company announcement explaining the move was found.
- A private Placement announced on July 9, 2026 sold 2,112,677 units at USD 1.42, so the current quote is about 74.6% below that price, calculated.
- Warrants in that placement could bring in about USD 6 million more if exercised for cash, adding potential share Supply at prices far above the current quote.
- The company filed a Patent application for its NELL-1 technology and announced an offering of about USD 5 million, per a summary page whose date was not shown.
Pre-Market Slide With No Announced Trigger
Bone Biologics was quoted at USD 0.3601 in pre-market, down 10.0%. No release, filing or analyst action dated November 11 to November 13, 2026 explaining the move was found. The latest price retrieved before today was USD 0.35, last updated on November 6, 2026, so the stock has been trading in a narrow band near 35 cents. The pre-market quote is the figure of record only for this session. At this price a small number of trades can move the quote sharply, spreads can be wide and a quoted move can reverse once the regular session opens. For context, a 10% fall at this price is about three and a half US cents.
Financing History and the Warrant Structure
The company develops a bone regeneration product candidate for spinal fusion based on the NELL-1 protein. On July 9, 2026 it announced a private placement of 2,112,677 shares, or pre-funded warrants, at USD 1.42 per unit, each with Series F and Series G warrants. Net proceeds were about USD 2.7 million after a placement agent fee of 7% plus other costs, and full cash exercise of the warrants could add about USD 6 million. The proceeds fund clinical work including trials in Australia, patent maintenance and working capital. The share price has since fallen far below the placement price. The structure of warrants alongside a sale of shares gives the buyers extra upside, and it can create a steady supply of shares if the warrants are later exercised.
Another Offering and the Sub-USD 1 Listing Question
A summary page lists a patent filing for NELL-1 and an offering of about USD 5 million to fund trials and extend the patent portfolio, but it gave no date or terms and the filing was not retrieved, so the size and price are unverified. Any new issuance would add shares to a base that is already small in value; a published figure near USD 2.4 million of market value, undated, shows how little capital the market assigns. A share price under USD 1 for 30 trading days can trigger a Nasdaq minimum bid notice, although none was found for this company. Cash runway was not found. Investors should also note that a published Market Value that small may mean limited trading liquidity.
Where Things Stand
No news explains the drop, so the move is best read as price pressure on a small, repeatedly financed company. Bone Biologics (NASDAQ:BBLG) was down 10.0% at USD 0.3601 in pre-market, roughly 75% below the July placement price. Warrants, a possible further USD 5 million offering and a sub-USD 1 quote all point to dilution risk, while Clinical Trials and patent work are the long-term story. Next markers are any offering terms, a listing notice and the next quarterly report. Quoted moves at this price can reverse.






Please wait processing your request...